MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    A modified Delphi panel to establish a threshold of meaningful progression on MDS-UPDRS Part III

    D. Trundell, L. Barrett, R. Rogers, E. Davies, S. Zanigni, N. Pross, G. Pagano, T. Nikolcheva, S. Cano (Welwyn Garden City, United Kingdom)

    Objective: To establish a threshold for meaningful progression on MDS-UPDRS Part III in an early-stage Parkinson's disease (PD) population (Hoehn & Yahr [H&Y] Stage I–II)…
  • 2022 International Congress

    Brain effects of high-intensity exercise on the dopamine system in individuals with Parkinson’s disease

    S. Tinaz, B. de Laat, G. Stanley, J. Hoye, J. Key, M. Hespeler, J. Ligi, Y. Huang, N. Nabulsi, E. Morris (New Haven, USA)

    Objective: We used PET imaging with 18F-FE-PE2I to quantify dopamine transporter availability and neuromelanin (NM)-MRI to measure the NM content in the substantia nigra (SN)…
  • 2022 International Congress

    NIMHANS Neuropsychological Battery for Elderly in Parkinson’s disease patients: Validation and diagnosis using MDS PD-MCI task force criteria in Indian population

    R. Yadav, R. Botta, K. Kumar, BM. Kutty, A. Mahadevan, PK. Pal (Bengaluru, India)

    Objective: To validate NIMHANS Neuropsychological Battery for Elderly( NNB-E) and evaluate cognitive impairment in Parkinson's disease (PD) patients in comparison with healthy controls. Background: Cognitive…
  • 2022 International Congress

    Early Synucleinopathy is Associated with Differential Regulation of Neurotransmission and Immune Related Genes

    J. Patterson, J. Kochmanski, A. Stoll, M. Kubik, C. Kemp, J. Howe, M. Duffy, K. Miller, A. Cole-Strauss, J. Beck, S. Counts, K. Steece-Collier, A. Bernstein, K. Luk, C. Sortwell (Grand Rapids, USA)

    Objective: Identification of gene expression changes in the rat substantia nigra pars compacta (SNpc) associated with early alpha-synuclein (a-syn) inclusion formation. Background: Accumulation of intracellular…
  • 2022 International Congress

    Antipsychotic use in Parkinson’s disease: a single center retrospective chart review

    S. Brooker, C. Yeh, D. Larson (Chicago, USA)

    Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…
  • 2022 International Congress

    A double-blind randomized clinical trial to evaluate the effects of Candesartan for Cognitive and Neuropsychiatric Impairment in Parkinson’s Disease

    J. Kulisevsky, S. Martinez-Horta, A. Campolongo, B. Pascual-Sedano, J. Marin-Lahoz, H. Bejr-Kasem, A. Puig-Davi, J. Pagonabarraga, J. Rodriguez-Antiguedad (Barcelona, Spain)

    Objective: To explore the feasibility of repurposing candesartan for the treatment of cognitive impairment and neuropsychiatric symptoms in PD. Background: There is an urgent need…
  • 2022 International Congress

    Parkinson`s disease in Pandemic Covid

    S. Galbineanu, A. Ailene (Brasov, Romania)

    Objective: SARS-CoV2 infection invades the brain through ACE2 receptors or the cytotoxic aggregation of proteins, including α-synuclein.Studies are uncertain on the risk of COVID and…
  • 2022 International Congress

    Emotion Recognition and Risk-Taking Behaviour in Early Parkinson’s Disease

    A. Slomp, D. de Waard, S. Vander Zee, S. Slingerland, J. Boertien, J. Spikman, T. van Laar, R. Huitema (Groningen, Netherlands)

    Objective: To assess the association between facial emotion recognition and traffic-related risk-taking behaviour in early Parkinson’s Disease (PD) patients. Background: Risk-taking behaviour is an important…
  • 2022 International Congress

    Automated quantification of facial bradykinesia through video in de-novo Parkinson’s disease

    M. Novotný, H. Růžičková, E. Růžička, P. Dušek, J. Rusz, T. Tykalová (Prague 6, Czech Republic)

    Objective: The purpose of this study was therefore to develop a fully automatic video-based hypomimia assessment tool and estimate the prevalence and characteristics of hypomimia…
  • 2022 International Congress

    Progressive Supranuclear Palsy (PSP) Vs Parkinson’s Disease (PD) – Whether Frontal Assessment Battery (FAB) Can Differentiate

    M. Kulsum, D. Das, S. Ananad (Kolkata, India)

    Objective: To find out the ability of the Frontal Assessment Battery (FAB) for quantitative analysis of the executive dysfunction of PSP and PD.To find out…
  • « Previous Page
  • 1
  • …
  • 214
  • 215
  • 216
  • 217
  • 218
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley